Radient Pharmaceuticals Corp. (RPC) Appoints Seasoned Director to Head North American Sales

QualityStocks would like to highlight Radient Pharmaceuticals (AMEX: RTC). The company is focused on developing and commercializing diagnostic tests that assist physicians in answering important clinical questions related to early disease detection, including its Onko-Sure® In Vitro Diagnostic (IVD) cancer test.

In the company’s news yesterday,

Radient Pharmaceuticals announced it has appointed Gary Giarrantano as director of North American Sales for the company, where he will be responsible for managing the company’s sales and marketing strategy, operations and Onko-Sure(R) IVD product sales.

Giarratano has more than 20 years of healthcare, sales and marketing leadership experience. He is recognized for his contributions in new market development for Carcinoembryonic Antigen (CEA), Prostate-Specific Antigen (PSA) and Human Papillomavirus (HPV), and led sales for the first company to secure U.S. FDA approval on each of these assays.

Giarratano’s sales experience includes positions with established and emerging healthcare and pharmaceutical companies, including Qiagen, Roche Diagnostics, AutoGenomics Inc., Sebia Inc., Esoterix Laboratory, PerkinElmer Life Sciences and Hybritech Inc.

Radient said that Giarratano’s proven track record in the industry makes the company confidant he can increase the market reach of Onko-Sure.

“Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,” Douglas MacLellan, chairman and CEO of Radient stated in the press release. “Giarratano has demonstrated talent in strategically aligning sales objectives with marketplace demands, and meeting those demands through proven sales performance. His wealth of expertise in the IVD industry combined with a proven ability to deliver results makes him an exceptional leader we believe will help propel sales of Onko-Sure to the next level.”

Giarratano has established key professional relationships with major healthcare companies such as Quest, Lab Corp., Mayo, Kaiser, MetroPath, UniPath, Summit Pathology, TriCore, Intermountain Health Care and other regional reference labs.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.